Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Disease Clinical Trial

Official title:

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00540007
• Other study ID #: 07-0233 / 201104227
• Status: Completed
• Phase: Phase 2
• First received: October 4, 2007
• Last updated: October 5, 2017
• Start date: September 6, 2007
• Est. completion date: September 1, 2016

Study information

• Verified date: October 2017
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).

Description:

Hodgkin lymphoma (HL), an uncommon but significant subtype of lymphoma, is divided into classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). Progress has been made in cHL therapy resulting in 5-year failure free survival rates between 61%-89% even in the setting of advanced stage or bulky disease. Patients who relapse however, have a variable prognosis ranging from a 8-year overall survival rate of less than 8% for patients who never achieve a remission to 54% for patients with a complete remission lasting greater than 12 months. High dose chemotherapy with autologous stem cell support is the standard of care for patients with relapsed cHL but for those that relapse despite aggressive salvage therapy 20 - 50%, with median remission durations of approximately 6 months. Furthermore, a subset of relapsed HL patients may not be candidates for aggressive salvage regimens. These novel salvage therapies are needed for relapsed/refractory cHL, especially agents without serious late toxicities are particularly attractive in this disease. Advances in the understanding of HL pathogenesis and lenalidomide's mechanisms of action provide substantial rationale for evaluating lenalidomide in HL patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: September 1, 2016
• Est. primary completion date: September 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy.

• Patients must have relapsed or progressed after at least one prior systemic cytotoxic chemotherapy; prior autologous or allogeneic stem cell transplantation is allowed.

• Measurable disease must be present either on physical examination or imaging studies (CT, MRI, PET/CT). Any tumor mass greater or equal to 1 cm is acceptable.

• Age > 18 years old.

• ECOG performance status of less than or equal to 2 at study entry

• Adequate hematologic, renal, hepatic function as defined by:

• Absolute neutrophil count greater than or equal to 1000 / uL

• Platelets greater than or equal to 50,000 / uL

• Serum creatinine less than or equal to 1.5X institution upper limit of normal (ULN)

• Total bilirubin less than or equal to 2.0 mg/dL

• AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN (if not attributed to cHL)

• Disease free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.

• Understand and voluntarily sign an informed consent form.

• Able to adhere to the study visit schedule and other protocol requirements

• Females of childbearing potential (FCBP)† must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.

• FCBP must have two negative serum or urine pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.

• Men must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.

• All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

• Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight

• All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist.

Exclusion Criteria:

• Patients who are candidates for high dose chemotherapy and stem cell transplantation and have not yet undergone stem cell transplantation should not be enrolled.

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

• Any condition, including the presence of laboratory abnormalities.

• Use of any other anti-cancer drug or therapy, including experimental, within 30 days of enrollment.

• Known hypersensitivity to thalidomide.

• The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.

• Any prior use of lenalidomide.

• Known positive for HIV or infectious hepatitis, type A, B or C.

• Pregnant or breastfeeding females.

• Concurrent use of other anti-cancer agents or treatments.

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma

Intervention

Drug:
• Lenalidomide

Locations

Country	Name	City	State
United States	Ohio State University	Columbus	Ohio
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Washington University	Saint Louis	Missouri
United States	Wake Forest University Medical School	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	Celgene Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004 Apr;4(4):314-22. doi: 10.1038/nrc1323. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL.	Overall response rate = CR + PR; Definitions per 2007 Cheson Lymphoma Response Criteria	Through 3.5 years from study entry or until disease progression
Secondary	Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL.	Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; The higher the grade the worse the adverse event was considered	30 days following the completion of treatment
Secondary	Cytostatic Overall Response Rate	Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months; Definitions per 2007 Cheson Lymphoma Response Criteria	From 6 months through 3.5 years after study entry
Secondary	Participant Response Rate in Relapsed or Refractory cHL.	-Definitions per 2007 Cheson Lymphoma Response Criteria	Through 3.5 years from study entry or until disease progression
Secondary	Time to Progression (TTP).	-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma.	Through 3.5 years from study entry or until disease progression
Secondary	Overall Survival (OS)	Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause.	Through 3.5 years from study entry or until disease progression
Secondary	Relapse Free Survival (RFS)		Through 3.5 years from study entry or until disease progression
Secondary	Event Free Survival (EFS).	-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death).	Through 3.5 years from study entry or until disease progression
Secondary	Duration of Response	-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started	Through 3.5 years from study entry or until disease progression

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine